Exhibit 10.1
INVESTOR RIGHTS AND LOCK-UP AGREEMENT
THIS INVESTOR RIGHTS AND LOCK-UP AGREEMENT (this “Agreement”) is entered into as of July 1, 2020, by and among Immatics N.V., a Dutch public limited liability company (the “Company”), the parties listed as Investors on Schedule I hereto (each, an “Investor” and collectively, the “Investors”).
WHEREAS, ARYA Sciences Acquisition Corp., a Cayman Islands exempted limited company (“ARYA”), the Company, Immatics Merger Sub 1, a Cayman Islands exempted company (“ARYA Merger Sub”), Immatics Merger Sub 2, a Cayman Islands exempted company (“IB Merger Sub”), and Immatics Biotechnologies GmbH, a German limited liability company (“GmbH”) have entered into that certain Business Combination Agreement, dated as of March 17, 2020 (as amended or supplemented from time to time, the “Business Combination Agreement”), pursuant to which, among other things: (i) each Participating Shareholder (as defined in the Business Combination Agreement) of GmbH exchanged his, her or its shares of GmbH for Ordinary Shares on the terms and subject to the conditions therein (the “Exchange”) and (ii) ARYA Merger Sub will merge with and into ARYA (the “First Merger”), with ARYA surviving as a wholly owned subsidiary of the Company;
WHEREAS, ARYA, ARYA Sciences Holdings, a Cayman Islands exempted company (“Sponsor”), Dr. David Hung, Dr. Todd Wider and Kevin Conroy (together with Sponsor, the “ARYA IPO Investors”) are parties to that certain Registration and Shareholder Rights Agreement, dated October 10, 2018 (the “Prior Agreement”);
WHEREAS, the ARYA IPO Investors currently hold (i) Class B ordinary shares, par value $0.0001 per share, of ARYA issued by ARYA prior to the consummation of ARYA’s initial public offering (collectively, the “Founder Shares”) and (ii) warrants to purchase Class A ordinary shares, par value $0.0001 per share (“Class A Shares”), of ARYA issued by ARYA simultaneously with the consummation of ARYA’s initial public offering (the “Sponsor’s Warrants”);
WHEREAS, the Founder Shares will automatically convert into Class A Shares at the time of the initial Business Combination (as defined in the Prior Agreement) on a one-for-one basis, subject to adjustment, on the terms and conditions provided in ARYA’s amended and restated memorandum and articles of association, as the same may be amended from time, and will be exchanged for Ordinary Shares in connection with the First Merger;
WHEREAS, Sponsor will forfeit all Sponsor’s Warrants at the consummation of the Business Combination;
WHEREAS, Perceptive Life Sciences Master Fund, Ltd, a Cayman Island exempted company (together with the ARYA IPO Investors, the “ARYA Investors”) has subscribed to purchase Ordinary Shares in the PIPE Financing (defined below) in connection with the consummation of the Business Combination.
WHEREAS, certain Investors (“GmbH Investors”) hold ownership interests in GmbH, consisting of ordinary shares (“GmbH ordinary shares”); shares designated as Series C preferred shares (“GmbH Series C Preferred Shares”); shares designated as Series D preferred shares (“GmbH Series D Preferred Shares”), and shares designated as Series E preferred shares (“GmbH Series E Preferred Shares” and together with GmbH ordinary shares, GmbH Series C Preferred Shares and GmbH Series D Preferred Shares, the “GmbH Shares”);